Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
Shiradkar R, Panda A, Leo P, Janowczyk A, Farre X, Janaki N, Li L, Pahwa S, Mahran A, Buzzy C, Fu P, Elliott R, MacLennan G, Ponsky L, Gulani V, Madabhushi A. Shiradkar R, et al. Among authors: fu p. Eur Radiol. 2021 Mar;31(3):1336-1346. doi: 10.1007/s00330-020-07214-9. Epub 2020 Sep 2. Eur Radiol. 2021. PMID: 32876839 Free PMC article.
Correction to: T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
Shiradkar R, Panda A, Leo P, Janowczyk A, Farre X, Janaki N, Li L, Pahwa S, Mahran A, Buzzy C, Fu P, Elliott R, MacLennan G, Ponsky L, Gulani V, Madabhushi A. Shiradkar R, et al. Among authors: fu p. Eur Radiol. 2021 Apr;31(4):2644. doi: 10.1007/s00330-020-07285-8. Eur Radiol. 2021. PMID: 32945970 No abstract available.
Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer.
Li L, Shiradkar R, Tirumani SH, Bittencourt LK, Fu P, Mahran A, Buzzy C, Stricker PD, Rastinehad AR, Magi-Galluzzi C, Ponsky L, Klein E, Purysko AS, Madabhushi A. Li L, et al. Among authors: fu p. Eur J Radiol Open. 2023 Jun 13;10:100496. doi: 10.1016/j.ejro.2023.100496. eCollection 2023. Eur J Radiol Open. 2023. PMID: 37396490 Free PMC article.
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Batts ED, Maisel C, Kane D, Liu L, Fu P, O'Brien T, Remick S, Bahlis N, Gerson SL. Batts ED, et al. Among authors: fu p. Cancer Chemother Pharmacol. 2007 Aug;60(3):415-21. doi: 10.1007/s00280-007-0442-7. Epub 2007 Mar 13. Cancer Chemother Pharmacol. 2007. PMID: 17354015 Clinical Trial.
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
Dowlati A, Posey J, Ramanathan RK, Rath L, Fu P, Chak A, Krishnamurthi S, Brell J, Ingalls S, Hoppel CL, Ivy P, Remick SC. Dowlati A, et al. Among authors: fu p. Cancer Chemother Pharmacol. 2009 Dec;65(1):73-8. doi: 10.1007/s00280-009-1005-x. Epub 2009 Apr 28. Cancer Chemother Pharmacol. 2009. PMID: 19399502 Free PMC article. Clinical Trial.
Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.
Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, Fu P, Janaki N, El-Fahmawi A, Shahait M, Kim J, Lee D, Yamoah K, Rebbeck TR, Khani F, Robinson BD, Shih NNC, Feldman M, Gupta S, McKenney J, Lal P, Madabhushi A. Leo P, et al. Among authors: fu p. Eur Urol Focus. 2021 Jul;7(4):722-732. doi: 10.1016/j.euf.2021.04.016. Epub 2021 Apr 30. Eur Urol Focus. 2021. PMID: 33941504 Free PMC article.
3,114 results